drugset / Trial / NCT02683421

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

NCT02683421

Phase 1 Completed 18 enrolled Navidea Biopharmaceuticals
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with active RA and concordance with clinical symptomology.

Timeline

Start
2016-07
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tilmanocept Diagnostic / imaging agent 50 ug Subcutaneous
Subject Tilmanocept Diagnostic / imaging agent 200 ug Subcutaneous

Indications